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Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hy-
perlipidemic hemodialysis patients. The incidence of atherosclerosis in
hemodialysis (HD) patients is very high. Major risk factors are aging,
lipid metabolism disturbances, high blood pressure, and smoking. High
blood pressure and hypertriglyceridemia, which is atherogenic in the
presence of smoking, are encountered very often in HD patients. The
effects of eicosapentaenoic acid (EPA) on plasma lipids and blood pres-
sure were studied for the first time in HD patients by the administra-
tion of capsules containing fish oil rich in EPA, which is known to
lower serum lipid concentration and blood pressure. We treated 12
hyperlipidemic patients (3 of type ha, 3 of type JIb, and 6 of type IV;
3 males, 9 females; 31 to 70 years of age; 4 to 90 months on HD) with
24 capsules (1.6 g EPA and 1.0 g docosahexaenoic acid) per day for 13
weeks. Serum triglycerides, total cholesterol, and phospholipid de-
creased significantly after capsule administration. The ratio of EPA to
arachidonic acid in serum increased significantly. There was a small
but statistically significant decrease in platelet count. Diastolic blood
pressure decreased at the end of the experiment. These effects of fish
oil are considered favorable for the prevention of atherosclerosis and
its subsequent diseases.
Effets d'une huile de poisson riche en acide eicosapentaénoIque sur les
lipides sériques chez des malades hemodialysés hyperlipidémiques.
L'incidence de l'athérosclérose chez les malades hémodialysés (HD)
est très élevée. Les facteurs de risque majeurs d'athérosclérose sont
l'age, les perturbations du métabolisme des lipides, une pression
artérielle élevée, et le tabagisme. Une pression artérielle élevée et une
hypertriglycéridemie, laquelle est athérogéne en presence d'un taba-
gisme, sont très souvent rencontrées chez les malades HD. Les effets
de l'acide eicosapentaénoIque (EPA) sur les lipides plasmatiques et Ia
pression artérielle ont été étudiés pour la premiere fois chez des
malades HD en administrant des capsules contenant une huile de Pois-
son riche en EPA, qui est connue pour abaisser la concentration en
lipides sériques et Ia pression artérielle. Douze malades hyperlipidé-
miques (trois de type ha, 3 de type Jib, et 6 de type IV; 3 hommes, 9
femmes, 31 a 70 ans; 4 a 90 mois en HD) ont été traités avec 24 cap-
sules (1,6 g d'EPA et 1,0 g d'acide docosahexénoique) par jour pen-
dant 13 semaines. Les triglycerides, Ic cholesterol total, et les phospho-
lipides seriques ont significativement diminué apres administration des
capsules. Le rapport de l'EPA a l'acide arachidonique dans le serum
s'est élevé significativement. Ii y a eu une diminution faible mais sig-
nificative du nombre de plaquettes. La pression artérielle diastolique a
baissé a Ia fin de l'expérience. Ces effets de l'huile de poisson sont
considérés favorables pour prévenir l'athérosclérose et les maladies qui
en résultent.
contributing factor may be the lipid metabolism disturbances,
especially hypertriglyceridemia, that are often encountered in
HD patients [2—6].
There are many clinical trials to correct the risk factors as-
sociated with premature atherosclerosis in HD patients. Many
of them are directed toward correction of disturbed lipid me-
tabolism, such as antihyperlipidemic drugs [7], dietary regi-
men [8—10], and carnitine [11]. Considering the nature of ath-
erosclerosis and its subsequent progression to thrombotic dis-
eases, one should take account of several other aspects of HD
patients, in addition to lipid metabolism disorder, to prevent
those diseases.
Since Dyerberg and Bang reported the favorable effects of w-
3 polyunsaturated fatty acids (PUFA) such as eicosapentae-
noic acid (EPA, C20:5, a-3) on the prevention of atheroscle-
rosis [12], there have appeared several clinical studies report-
ing depression of platelet function/number, decreases in blood
pressure, or improvement of serum lipids or of blood rheology
resulting from the administration of fish oil or EPA concen-
trate [13—24].
In this study we administered fish oil to HD patients to take
advantage of the multifactorial effects of to-3 PUFA on risk fac-
tors for atherosclerosis,
Methods
Twelve hyperlipidemic HD patients were investigated. They
were 31 to 70 years of age (3 males and 9 females). Duration of
HD varied from 4 to 90 months (mean, 31 months) and was
mostly over 12 months. The etiologies of kidney impairment
were chronic glomerulonephritis in 4, chronic pyelonephritis in
3, and "not defined" in 5.
None of these patients were treated with antihyperlipidemic
drugs, aritihypertensive drugs, steroids, insulin, or 13-blockers.
The purpose of the study was explained to the patients, and in-
formed consent was obtained from them. They were advised
not to change their dietary habits during the study. They had
With improvements in hemodialysis (HD) techniques, the
short-term prognosis of HD patients is getting better. Accel-
erated atherosclerosis, however, is a frequent finding [1]. A
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Fatty acid % (weight)
14:0
16:0
16:1
18:0
18:1
18:2
18:4
20:1
20:4, w-6 (AA)
20:5, w-3 (EPA)
22:1
22:5
22:6, w-3 (DHA)
24:1
a Figures before the ratio sign (":") are the number of carbons
incuded in a fatty acid molecule; figures after the sign are the number of
double bonds in the fatty acid. w defines the position of the first double
bond from the methyl end of the fatty acid. AA is arachidonic acid;
EPA, eicosapentaenoic acid, DHA, docosahexaenoic acid.
been dialyzed three times per week prior to the study (Mon-
day-Wednesday-Friday or Tuesday-Thursday-Saturday), and
the schedule of HD treatment was not changed throughout the
study.
Fish oil rich in w-3 PUFA was obtained by wintering crude
sardine oil and was encapsulated in gelatin coat. Each capsule
contained 400 mg of oil with 0.2% vitamin E as a preservative
and for the prevention of possible vitamin E deficiency. The
fatty acid composition is shown in Table 1. The patients were
given 24 capsules [1.6 g of EPA and 1.0 g of docosahexaenoic
acid (DHA), 19 mg of vitamin E, and about 90 calories as a
wholel per day for 13 weeks. Blood samples for the measure-
ments of serum lipid levels, blood viscosity, and plasma fatty
acid composition were obtained before and 4 and 13 weeks af-
ter the initiation of fish oil treatment. Sampling was carried out
on Monday or Tuesday between 8 and 9 A.M. just before HD
treatment and after at least 12 hours of fasting.
The fatty acid composition of the total lipid extract of plasma
was determined as previously described [251. In brief, plasma
was separated from heparinized blood. Extraction of total
lipids from plasma was carried out according to the method of
Folch, Lees, and Stanley [261. The extract was saponified and
then acidified to give free fatty acids. Those free fatty acids
were methylated by methanolic boron trifluoride and sepa-
rated by gas chromatography.
Serum cholesterol, phospholipid [27], and triglyceride were
measured enzymatically. HDL-cholesterol was measured en-
zymatically after separation of the lipoproteins by electropho-
resis. Other characteristics of the general blood chemistry and
blood count were determined every week or every other week
using standard techniques.
Heparinized blood samples, and plasma separated from it,
were used for the determination of viscosity. Measurement was
carried out at 370 C using a viscometer (Biorheolizer Model E,
Tokyo Keiki, Tokyo) at shear rates of 37.6 and 376 per second
for whole blood viscosity and 376 per second for plasma vis-
cosity [28].
Blood pressure was measured just before the first HD treat-
ment of every week. Four consecutive weekly measurements
16:0 22.7 1.3 23.0 1.5 23.0 1.5
16:1 3.5 1.3 3.7 1.1 3.8 1.0
18:0 5.0 0.8 5.0 0.7 5.3 1.1
18:1 22.6 3.3 19.1 2.3' 20.1 2.4k'
18:2 31.5 4.9 29.7 5.4° 27.3 5.3°
18:3 1.1 0.4 0.9 0.2 0.9 0.2
20:4 (AA) 3.8 1.1 3.9 0.7 3.5 0.7
20:5 (EPA) 1.2 0.7 4.4 Ø7d 5.3 0.9d'
22:6 (DHA) 1.9 0,6 2.7 0.6d 2.9 0.6da
a Results are expressed as the percentages of each fatty acid in the
total fatty acid content of plasma. Values are the means SD (N = 12).
Only fatty acids comprising more than 1.0% of total plasma fatty acids
are listed.
b P < 0.01, c P < ooo5, d P < 0.001, compared to values before
beginning of study).
P < 0.025, P < 0.005, compared to values after 4 weeks of
treatment.
were averaged and compared with the average blood pressure
during the 4 weeks prior to fish oil administration.
Data were expressed as the means SD and treated by
paired t test.
Results
The administration of fish oil capsules was tolerated well by
all patients. No side effects were observed. One patient who
had long been complaining of headaches stopped complaining
after 3 to 4 weeks of fish oil treatment. This may have been a
placebo effect. Body weight increased 0.6 kg on the average
but not significantly at the end of study.
In all patients, the ratios of EPA and DHA to total fatty ac-
ids in plasma lipids increased significantly after 4 and 13 weeks
of fish oil treatment (Table 2). This increment roughly corre-
sponds to the decrease in fatty acids of 18:1 and 18:2. The per-
centage of other fatty acids, including arachidonic acid, did not
change significantly throughout the study.
Total triglycerides, total cholesterol, and phospholipid in se-
rum decreased significantly after 4 and 13 weeks of fish oil
treatment (Fig. 1). HDL-cholesterol levels showed a small but
insignificant increase. Serum free fatty acid did not change dur-
ing the study.
Changes in blood pressure are shown in Table 3. There was
a slight but statistically significant decrease in diastolic pres-
sure after 12 weeks of fish oil treatment.
Platelet count decreased from 156 49 (x 103/mm3) to 126
41 after 13 weeks (P < 0.005).
Whole blood and plasma viscosity did not change signifi-
cantly. Also, the whole blood viscosity standardized by hema-
tocrit did not show any significant change throughout the
study.
Discussion
Premature atherosclerosis is an important risk factor in re-
nal diseases and a major factor limiting the survival of patients
on regular maintenance HD [2]. For the prevention of pre-
mature atherosclerosis, correction of lipid disturbances is con-
sidered important. Several studies have reported possible
mechanisms of the triglyceride metabolism disturbance. These
Table 1. Fatty acid composition of fish oil capsule' Table 2. Effect of fish oil capsule administration on total plasma fatty
acid composition'
Fatty acid Before therapy After 4 weeks After 13 weeks
6.1
13.4
10.4
1.8
13.8
3.4
3.6
6.0
1.0
16.8
5.0
3.2
10.6
2.0
*Before 4 weeks 13 weeks
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Fig. 1. Changes in serum triglycerides (open columns), total choles-
terol (horizontally hatched columns), and phospholipids (vertically
hatched columns) after fish oil administration. Values given are the
means SD (N = 12) and are compared to the values obtained before
fish oil administration. Statistical significance is denoted by asterisks:
*p < 0.025, < 0.005, ***p < 0.001.
Table 3. Change in blood pressurea
Before
treatment
After 4
weeks
After 8
weeks
After 12
weeks
Systolic 125 18 129 19 125 15 127 17
Diastolic 75 12 77 13 75 9 68 9b
a The averages of four consecutive measurements are shown (mean
SD, N = 12). Blood pressure "before treatment" is the average of
weeks —3 toO; at 4 weeks it is the average of weeks 2 to 5; at 8 weeks it
is the average of weeks 6 to 9; and at 12 weeks it is the average of weeks
10 to 13.
P < 0.05.
studies tend to confirm that it is principally the catabolism of
triglyceride that is disturbed [29—331.
In this study, we observed a decrease in triglycerides as a re-
suit of fish oil treatment. The ability of fish oil to lower triglyc-
erides is well known [341, but the mechanism of action of fish
oil is not clear. w-3 PUFA may change the microenvironment
(fluidity) of lipoproteins so that they may be catabolized easier
[341.
As for the cholesterol-lowering effect, the following mecha-
nisms have been proposed [341: (1) increased fecal steroid ex-
cretion, (2) change in the fatty acid composition of lipopro-
teins, and (3) changes in the rates of synthesis and/or catabo-
lism of lipoproteins.
Only a Cew clinical studies with patients using fish oil have
been reported thus far. Hay, Durber, and Saynor administered
fish oil to 13 patients with ischemic heart disease [201. They ob-
served a prolongation of platelet survival time, a fall in platelet
count, and also falls in platelet factor 4 and /3-thromboglobulin
levels in plasma. Fish oil is known to modify hemostatic func-
tions in several ways [23], in addition to its effects on plate-
lets. For example, the bleeding times of Eskimos who eat about
5 g of EPA per day are much longer than those of Danish
people [12].
In HD patients, the disturbance of platelet function is com-
plex [35]. Because they are treated with heparin continuously,
the depression of hemostatic function should be carried out
very carefully. We used a dose of 1.6 g of EPA per day, be-
cause the sum of daily EPA ingestion from meals and this dose
of EPA is roughly equal to the amount of EPA in the normal
diet of fishing people in Japan [131. Throughout the study we
did not observe any bleeding tendency in patients adminis-
tered fish oil.
Miettinen et al [361 suggested that a decrease in the 18:2
composition of fatty acid in serum phospholipids is an indepen-
dent risk factor for coronary heart disease. However, their sug-
gestion appears to be applicable only to those who do not eat
a seafood diet, because in Greenland Eskimos, in whom ath-
erosclerosis and coronary heart disease are very rare, levels of
18:2 fatty acid in serum phospholipids are less than one third
of those of Caucasian Danes [37]. Therefore, the decrease in
18:2 fatty acid in the serum of our subjects after the adminis-
tration of fish oil capsules is not considered to be a risk factor
for coronary heart disease.
We were not able to lower blood viscosity in HD patients.
In normal volunteers it was shown that blood viscosity could
be depressed by EPA-rich fish oil [19] and EPA concentrate
[23j. In HD patients, concentrations of plasma components
change significantly from one HD session to the next. This may
be the reason why we were not able to observe any significant
change in viscosity. Red blood cell deformability, which has
been shown to be decreased in HD patients [381, may have
been increased in our study, since red cell deformability has
been reported to be improved by EPA ethylester administra-
tion [231.
In experiments with healthy volunteers, blood pressure was
depressed by fish oil administration slightly but by a statisti-
cally significant amount [18, 21]. This effect of fish oil is also
important in preventing atherosclerosis.
A specific factor to HD patients that may be atherogenic is
hyperparathyroidism. After 13 weeks of fish oil administra-
tion, parathyroid hormone levels were slightly depressed al-
though not significantly (data not shown).
In conclusion, the administration of fish oil to HD patients
was carried out without any serious side effects. Some favor-
able effects were noted: decreases in triglyceride and total cho-
lesterol levels in serum and decreases in blood pressure. Fur-
ther study of fish oil treatment in HD patients seems to be jus-
tified, but any extrapolation of our observations beyond the 13-
week period of this study should be made with caution.
Acknowledgments
EPA capsules were kindly supplied by Nippon Suisan Kaisha, Ltd.,
and Nissui Seiyaku Co., Ltd.
Reprint requests to Dr. T. Hamazaki, 1st Department of Internal
Medicine, Toyama Medical and Pharmaceutical University, Toyama
City, Toyama 930-01, Japan
References
1. LINDNER A, CHARRA B, SI-IERRARD Di, SCRIBNER BH: Acceler-
ated atherosclerosis in prolonged maintenance hemodialysis. N
Engl J Med 290:697—701, 1974
2. Cs.MP DG: Plasma lipid alterations in patients with chronic renal
disease. CRC Crit Rev Clin Lab Sci 17:77—101, 1982
3. BAGOADE J, CASARETTO A, ALBERS J: Effects of chronic uremia,
hemodialysis and renal transplantation on plasma lipids and
lipoproteins in man. J Lab Clin Med 87:37—48, 1976
4. CHAN MK, VARGHESE Z, MOORHEAD iF: Lipid abnormalities in
uremia, dialysis, and transplantation. Kidney mt 19:625—637, 1981
84 Hamazaki ci al
5. Lewis B: Hypothesis into theory—the development of aetiologi-
cal concepts of ischemic heart disease: A review, J R Soc Med
71:809, 1978
6. HAIRE HM, SHERRARD Di, SCARDAPANE D, CURTIS FK,
BRUNZELL JD: Smoking, hypertension, and mortality in a main-
tenance dialysis population. Cardiovasc Med 3:1163—1168, 1978
7. GOLDBERG AP, APPLEBAUM-BOWDEN DM, BIERMAN EL,
HAZZARD WR, HAAS LB, SHERRARD DJ, BRUNZELL JD, HUT-
TUNEN JK, EHNHOLM C, NIKKILA EA: Increase in lipoprotein
lipase during clofibrate treatment of hypertriglyceridemia in pa-
tients on hemodialysis. N Engl J Med 301:1073—1076, 1979
8. OKUBO M, TSUKAMOTO T, YONEDA T, HOMMA Y, NAKAMURA H,
MARUMO F: Deranged fat metabolism and the lowering effect of
carbohydrate-poor diet on serum triglycerides in patients with
chronic renal failure. Nephron 25:8—14, 1980
9. SANFELIPPO ML, SWENSON RS, REAVEN GM: Response of plasma
triglycerides to dietary change in patients on hemodialysis. Kidney
In! 14:180—186, 1978
10. SPITZ N, MLSHKEL MA: Effects of dietary fats on plasma lipids and
lipoproteins: A hypothesis for the lipid-lowering effect of unsatur-
ated fatty acids. J Clin Invest 48:78—86, 1969
11. LACOUR B, DI GIULIO S, CHANARD i, CIANCIONI C, HAGUET M,
LEBKIRI B, BASILE C, DRUEKE T, ASSAN R, FUNCK-BRENTANO
iL: Carnitine improves lipid anomalies in haemodialysis patients.
Lancet 2:763—766, 1980
12. DYERBERG J, BANG HO: Atherogenesis and hemostasis in Eski-
mos: The role of the prostaglandin-3 family. Haemostasis
8:227—233, 1979
13. HIRAI A, HAMAZAKI T, TERANO T, NISHIKAWA T, TAMURA T,
KUMAGAI A, SAJIKI J: Eicosapentaenoic acid and platelet func-
tion in Japanese. Lancet 2:1132, 1980
14. HARRIS WS, CONNOR WE: The effects of salmon oil upon plasma
lipids, lipoproteins and triglyceride clearance. Trans Assoc Am
Physicians 43:148—155, 1980
15. BROX iH, KILLIE J-E, GUNNES S, NORD$Y A: The effect of cod-
liver oil and corn oil on platelets and vessel wall in man. Thromb
Haemostas 46:604—611, 1981
16. GOODNIGHT SH iR, HARRIS WS, CONNOR WE: The effects of di-
etary w-3 fatty acids on platelet composition and function in man:
A prospective, control study. Blood 58:880—885, 1981
17. THORNGREN M, GUSTAFSON A: Effects of 11-week increase in di-
etary eicosapentaenoic acid on bleeding time, lipids, and platelet
aggregation. Lancet 2:1190—1193, 1981
18, SANDERS TAB, VICKERS M, HAINES AP: Effects on blood lipids
and haemostasis of a supplement of cod-liver oil, rich in eicosa-
pentaenoic and docosahexaenoic acids, in healthy young men. C/in
Sci 61:317—324, 1981
19. KOBAYASHI S, HIRAL A, TERANO T, HAMAZAKI T, TAMURA Y,
KUMAGAI A: Reduction in blood viscosity by eicosapentaenoic
acid. Lance! 2:197, 1981
20. HAY CRM, DURBER AP, SAYNOR R: Effect of fish oil on platelet
kinetics in patients with ischemic heart disease. Lance!
1:1269—1272, 1982
21. DYERBERG i, MORTENSEN JZ, NIELSEN AH, SCHMIDT EB: n-3
Polyunsaturated fatty acids and ischemic heart disease. Lance!
2:614, 1982
22. SAYNOR R, VEREL D: Eicosapentaenoic acid, bleeding time, and
serum lipids. Lancel 2:272, 1982
23. TERANO T, HIRAI A, HAMAZAKI T, KOBAYASHI 5, FUJITA T,
TAMURA Y, KUMAGAI A: Effect of oral administration of highly
purified eicosapentaenoic acid on platelet function, blood viscos-
ity and red cell deformability in healthy human subjects. Athero-
sclerosis 46:321—331, 1983
24. SANDERS TAB, ROSHANAI F: The influence of different types of w-
3 polyunsaturated fatty acids on blood lipids and platelet function
in healthy volunteers. C/in Sci 64:91—99, 1983
25. HAMAZAKI T, HIRAI A, TERANO T, SAJIKI i, KONDO S, FUJITA T,
TAMURA T, KUMAGAI A: Effects of orally administered ethylester
of eicosapentaenoic acid (EPA; C20:5 w-3) on PGI2-like substance
production by rat aorta. Prostaglandins 23:557—567, 1982
26. FOLCH J, LEES M, STANLEY GHS: Simple method for the isola-
tion and purification of total lipid from animal tissue. J Biol Chem
226:497—509, 1957
27. SUGIvRA M, OIKAWA T, HIRANO K: An enzymic determination
for serum phospholipid. C/in Chim Acta 89:447—453, 1978
28. HAMAZAKI T, SHI5I-IlDo H: Increase in blood viscosity due to al-
cohol drinking. Thromb Res 30:587—594, 1983
29. M0RDASINI R, FREY F, FLURY W, KLOSE G, GRETEN H: Selec-
tive deficiency of hepatic triglyceride lipase in uremic patients. N
EnglJ Med 297:1362—1366, 1977
30. HUTTUNEN JK, PASTERNACK A, VANTINNEN T, EFINHOLM C,
NIKKILA EA: Lipoprotein metabolism in patients with chronic ur-
emia. Acta Med Scand 204:211—218, 1978
31. STAPRANS I, FELTS iM, ZACFIERLE B: Apoprotein composition of
plasma lipoproteins in uremic patients on hemodialysis. C/in Chim
Acta 93:135—143, 1979
32. IBEL5 SL, REARDON MF, NE5TEL Pi: Plasma post-heparin lipo-
lytic activity and triglyceride clearance in uremic and hemodi-
alysis patients and renal allograft recipients. J Lab Cl/n Med
87:648—658, 1976
33. BOHMER T, BERGREM H, EIKLID K: Carnitine deficiency induced
during intermittent haemodialysis for renal failure. Lance!
1:126—128, 1978
34. GOODNIGHT SH JR, HARRIS WS, CONNOR WE, ILLINGWORTH DR:
Polyunsaturated fatty acids, hyperlipidemia, and thrombosis.
Arteriosclerosis 2:87—113, 1982
35. REMUZZI G, BENIGNI A, D0DEsINI P, SCI-IEIPPATI A, GOTTI E,
LIvI0 M, MECCA 0, DONATI MB, DE GAETANO G: Platelet func-
tion in patients on maintenance hemodialysis: Depressed or en-
hanced? C/in Nephrol 17:60—63, 1982
36. MIETTINEN TA, NAUKKARINEN V. HUTTUNEN 1K, MATTILA S,
KUMLIN T: Fatty-acid composition of serum lipids predicts myo-
cardial infarction. Br Mcdi 205:993—996, 1982
37. DYERBERG J, BANG HO, HJØRNE N: Fatty acid composition of the
plasma lipids in Greenland Eskimos. Am J C/in Nu!r 28:958—966,
1975
38. KHwCHI Y, KOYAMA T, KOYAMA Y, TOZAWA S, ARAI T, Ho-
RIMOTO M, KAKIUCHI Y: Red blood cell deformability in renal fail-
ure. Nephron 30:8—14, 1982
